Market Risers: Allergy Therapeutics, Antofagasta, AstraZeneca, BAE Systems

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

Shares in Allergy Therapeutics found using EPIC: LON:AGY has climbed 15.32% or 2.13 points throughout today’s trading session so far. Traders have remained optimistic throughout the session. Range high for the period has seen 16 and a low of 14.8. The number of shares traded by this point in time totalled 263,533 while the daily average number of shares exchanged is 584,649. A 52 week high for the stock is 21.5 about 7.62 points in difference to the previous days close of business and a 52 week low sitting at 7 making a difference of 6.88 points. Allergy Therapeutics now has a 20 moving average of 13.89 and a 50 day simple moving average now of 15.42. The current market capitalisation is £102.34m at the time of this report. The share price is in GBX. Mcap is measured in GBP. This article was written with the last trade for Allergy Therapeutics being recorded at Friday, November 20, 2020 at 11:51:36 AM GMT with the stock price trading at 16 GBX.

Stock in Antofagasta company symbol: LON:ANTO has increased 2.78% or 30.5 points during the course of today’s session so far. Buyers have so far held a positive outlook during this period. Range high for the period has seen 1132.5 and a low of 1100.5. Volume total for shares traded at this point reached 239,427 with the daily average traded share volume around 1,476,358. A 52 week high for the stock is 1165.5 which comes in at 68.5 points difference from the previous days close and putting the 52 week low at 575 which is a difference of 522 points. Antofagasta now has a 20 SMA at 1085.03 and now the 50 day moving average of 1068.65. The market cap now stands at £11,122.18m at the time of this report. The currency for this stock is GBX. Market cap is measured in GBP. This article was written with the last trade for Antofagasta being recorded at Friday, November 20, 2020 at 11:51:02 AM GMT with the stock price trading at 1127.5 GBX.

Shares of AstraZeneca found using EPIC: LON:AZN has stepped up 1.98% or 161 points during today’s session so far. Buyers have remained optimistic throughout the trading session. The periods high figure was 8323.93 dropping as low as 7874. The total volume of shares exchanged through this period comes to 705,590 with the daily average at 1,971,960. The 52 week high for the shares is 10120 amounting to 1995 points difference from the previous days close and the 52 week low at 5871 which is a difference of 2254 points. AstraZeneca now has a 20 moving average of 8368.49 and also a 50 day SMA of 8449.44. Market capitalisation is now £108,737.80m at the time of this report. The currency for this stock is GBX. Market cap is measured in GBP. This article was written with the last trade for AstraZeneca being recorded at Friday, November 20, 2020 at 11:53:52 AM GMT with the stock price trading at 8286 GBX.

Shares of BAE Systems ticker code: LON:BA has climbed 3.51% or 17.8 points during the course of today’s session so far. Buyers have stayed positive throughout the trading session. The high for the period has reached 531.8 meanwhile the session low reached 505. Volume total for shares traded during this period was 4,495,943 whilst the average number of shares exchanged is 10,354,335. The 52 week high price for the shares is 672.8 amounting to 165 points difference from the previous close and the 52 week low at 395.9 a difference of some 111.9 points. BAE Systems now has a 20 SMA of 457.67 and also a 50 day moving average at 483.68. This puts the market cap at £16,912.24m at the time of this report. The stock is traded in GBX. Mcap is measured in GBP. This article was written with the last trade for BAE Systems being recorded at Friday, November 20, 2020 at 11:53:51 AM GMT with the stock price trading at 525.6 GBX.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.
AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy.

Search

Search